Stock AnalizPersonalis, Inc. PSNL
Medical Specialities · IPO 2019 · data as of November 13, 2026
Personalis, Inc. (PSNL) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to September 30, 2026 it had revenue of $81M and net income of -$119M, a net margin of -147.7%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -29%.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $81M | $70M | $85M | $73M | $65M | $85M | $79M | $65M | $38M | $9M |
| Net income | -$119M | -$81M | -$81M | -$108M | -$113M | -$65M | -$41M | -$25M | -$20M | -$24M |
| Free cash flow | -$108M | -$79M | -$47M | -$67M | -$120M | -$82M | -$46M | -$26M | -$2M | -$5M |
| EPS (diluted) | $-1.17 | $-0.91 | $-1.37 | $-2.25 | $-2.48 | $-1.49 | $-1.20 | $-1.39 | $-6.49 | $-7.78 |
| Net margin | -147.7% | -116.7% | -96.1% | -147.4% | -174.2% | -76.3% | -52.5% | -38.5% | -52.6% | -251.2% |
| ROIC | — | -23.2% | -22.0% | -49.5% | -34.5% | -14.1% | -16.2% | -16.3% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $15.17, 3% below the current price; targets range from $13.00 to $16.25; the consensus rating is “Hold”; expected EPS is $-1.16 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Personalis pay a dividend?
Not currently.
Is Personalis a good stock to buy?
We do not give buy or sell advice. Personalis scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.